Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

573
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
573
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

395
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
395
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

837
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
837
Angina IV: Management01:26

Angina IV: Management

408
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
408
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.5K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Managing remnant cholesterol: role of fenofibrate-statin therapy in reducing triglyceride-rich lipoproteins.

Frontiers in cardiovascular medicine·2026
Same author

Dosage of lipoproteins for risk management according to guidelines.

Vascular diseases (Paris, France)·2026
Same author

Lipid management in high cardiovascular risk patients in France: a comparison with rest of Europe patients from 1-year follow-up of SANTORINI.

Frontiers in cardiovascular medicine·2026
Same author

Not all fibrates are made equal: Learning from biology and clinical trials.

Atherosclerosis·2025
Same author

Higher EPA levels and EPA/DHA Ratios Are associated with Lower Cardiovascular Mortality Post-Myocardial Infarction.

European journal of preventive cardiology·2025
Same author

Optimizing oral low-density lipoprotein cholesterol-lowering therapy in statin-intolerant patients: A simulation study in France.

Archives of cardiovascular diseases·2025

Related Experiment Video

Updated: Mar 22, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Statin combination therapy and cardiovascular risk reduction.

Peter P Toth1, Michel Farnier2, Joanne E Tomassini3

  • 1CGH Medical Center, Sterling, Illinois, & Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Future Cardiology
|April 16, 2016
PubMed
Summary

Statin therapy effectively lowers LDL-C to reduce cardiovascular disease (CVD) risk. Combination therapies, including ezetimibe with statins, show promise for patients not reaching LDL-C goals.

Keywords:
CETPPCSK9bile acid sequestrantscombination therapyezetimibefibratesniacinomega 3-polyunsaturated long-chain fatty acidsstatin

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Related Experiment Videos

Last Updated: Mar 22, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Lowering low-density lipoprotein cholesterol (LDL-C) with statins is proven to reduce cardiovascular disease (CVD) risk.
  • Guidelines recommend statins as first-line therapy for managing CVD risk.
  • Many high-risk patients fail to achieve optimal LDL-C levels with statin monotherapy.

Purpose of the Study:

  • To review current evidence on statin combination therapy for cardiovascular outcomes.
  • To discuss the role of nonstatin agents in enhancing LDL-C reduction.
  • To highlight emerging lipid-lowering therapies.

Main Methods:

  • Literature review of clinical trials and guidelines.
  • Analysis of studies evaluating statin monotherapy versus combination therapy.
  • Overview of ongoing research on novel lipid-lowering agents.

Main Results:

  • Ezetimibe combined with simvastatin demonstrated improved cardiovascular event reduction compared to simvastatin alone in acute coronary syndrome patients.
  • Previous combination therapy approaches have yielded neutral findings.
  • Newer agents like PCSK9 and CETP inhibitors are under development.

Conclusions:

  • Statin combination therapy, particularly with agents like ezetimibe, offers a potential strategy for patients unresponsive to monotherapy.
  • Further research into novel agents is crucial for optimizing CVD risk management.
  • Achieving optimal LDL-C goals remains a key objective in cardiovascular prevention.